A Mycobacterium tuberculosis antigen fusion protein, its encoding gene, and its applications

By preparing a Mycobacterium tuberculosis antigen fusion protein, the problems of low accuracy and long detection time in existing tuberculosis tests have been solved, achieving efficient and low-cost tuberculosis diagnosis, which is applicable to trivalent subunit vaccines and diagnostic kits.

CN117586419BActive Publication Date: 2026-11-17NEIJIANG NORMAL UNIV
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202311480294.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-11-08
Publication Date
2026-11-17
Estimated Expiration
2043-11-08

AI Technical Summary

Technical Problem

Existing tuberculosis detection technologies suffer from low accuracy and long waiting times. In particular, bacterial culture methods are time-consuming, require expensive equipment, and have a high false positive rate. Immunological tests have poor specificity, and molecular diagnostic technologies are costly and not suitable for rapid on-site testing.

Method used

A Mycobacterium tuberculosis antigen fusion protein, including CFP-10, Rv3369, and ESAT-6 proteins, was prepared. Through codon optimization and restriction site design, a recombinant plasmid was constructed and expressed in Escherichia coli. The fusion protein was purified to obtain high-yield, low-cost fusion proteins for the development of trivalent subunit vaccines and diagnostic kits.

Benefits of technology

It achieves highly sensitive and specific tuberculosis diagnosis, can identify different types of tuberculosis patients, simplifies operation and reduces costs, and is suitable for rapid on-site testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117586419B_ABST
    Figure CN117586419B_ABST
Patent Text Reader

Abstract

This invention discloses an antigen fusion protein of Mycobacterium tuberculosis, its encoding gene, and its applications, relating to the field of genetic engineering technology. The antigen fusion protein comprises Mycobacterium tuberculosis CFP-10 protein, Rv3369 protein, and ESAT-6 protein linked by a linker peptide, and its amino acid sequence is shown in SEQ ID NO: 1. The fusion antigen protein prepared by this invention has high yield, low cost, simple operation, and good immunogenicity, and can be used for the subsequent development of trivalent subunit vaccines and diagnostic kits. It can lay the foundation for the development of a promising new diagnostic reagent for tuberculosis, and can also effectively differentiate and diagnose different types of tuberculosis patients.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of genetic engineering technology, specifically to an antigen fusion protein of Mycobacterium tuberculosis, its encoding gene, and its applications. Background Technology

[0002] Tuberculosis (TB) is a chronic infectious disease primarily transmitted through the respiratory tract, caused by Mycobacterium tuberculosis (MTB). According to reports, one-third of the world's population is currently latently infected with MTB, with 8 to 10 million new cases and 3 million deaths annually. my country faces a severe TB epidemic, ranking second in the world in terms of the number of TB patients, accounting for approximately one-quarter of global cases. It is one of the 22 countries with a high TB ​​burden, and the direct economic losses from TB exceed 4 billion yuan annually. Therefore, implementing effective TB control strategies nationwide is urgently needed.

[0003] Since tuberculosis is primarily transmitted through droplets, early diagnosis is crucial. Early diagnosis using simple, rapid, and accurate laboratory tests is essential for controlling the tuberculosis epidemic. However, the current diagnostic methods for tuberculosis are unsatisfactory. In vitro mycobacterial isolation and culture is the gold standard for diagnosing tuberculosis, but its drawbacks include a long culture period (approximately 6 weeks) and a high false-positive rate. In recent years, the Bactec mycobacterial culture / identification / antimicrobial susceptibility testing system, applied clinically, has shortened the detection time for positive samples to an average of 9 days, and the identification and antimicrobial susceptibility testing time to an average of 4 days. However, Bactec instruments are expensive, requiring imported patented liquid culture media, resulting in high costs. Furthermore, the method still relies on bacterial culture; whether detecting bacteria or metabolites, detection requires the natural growth of mycobacteria to accumulate a sufficient bacterial load. Since mycobacterial growth is relatively slow, these methods struggle to overcome the limitation of being "slow."

[0004] Among the immunological detection methods for tuberculosis, the most commonly used is the PPD test, which uses the body's allergic reaction to injected PPD to determine whether the body has been infected with Mycobacterium tuberculosis, serving as an auxiliary diagnostic indicator. However, because PPD contains many antigens common to mycobacteria, such as BCG vaccination, a positive PPD test result cannot differentiate between infection with the Mycobacterium tuberculosis complex and exposure to non-tuberculous mycobacteria in the environment or sensitization after BCG vaccination. The PPD skin test has poor diagnostic specificity, and the Mycobacterium tuberculosis infection rate obtained from epidemiological surveys of tuberculosis using this method does not truly reflect the actual situation of Mycobacterium tuberculosis infection in the population. Furthermore, patients with severe pulmonary tuberculosis often show negative results due to weakened immunity, all of which significantly reduce its clinical value. In addition, molecular diagnostic technologies that have been developed in recent years, such as PCR, PCR-RFLP, real-time PCR, and gene chip technology, have greatly shortened the detection time, but these technologies often require expensive instruments, have false positive and false negative problems, and have high requirements for laboratory hardware and the quality of testing personnel. Therefore, they are not very suitable for rapid on-site testing, early screening, and diagnosis.

[0005] Tuberculosis (TB) is a chronic, debilitating disease. Patients develop various specific antibodies during its long course, making serological testing a crucial basis for TB diagnosis. Serological immunodiagnostic methods based on specific antigen-antibody reactions are favored due to their advantages such as short processing time, simplicity, readily available samples, and wide applicability. After invading a host, Mycobacterium tuberculosis secretes multiple antigens, which may vary within the host depending on the individual patient's immune background and disease progression, exhibiting different antibody profiles. In recent years, in-depth studies have been conducted on culture filtrates of Mycobacterium tuberculosis, isolating various secreted antigens such as MPT64, PT70, MPT63, Ag85, CPF10, and ESAT6. However, research has found that none of these antigens is highly sensitive enough to detect TB antibodies; each antigen can only detect a subset of infected individuals, leading to varying degrees of missed diagnoses when using a single antigen for differential diagnosis. Therefore, the combined detection of multiple Mycobacterium tuberculosis-specific antigens through fusion can improve the sensitivity and specificity of diagnostic reagents, representing a future direction for TB diagnosis.

[0006] In summary, current tuberculosis testing still suffers from low accuracy and long waiting times for results. Summary of the Invention

[0007] Based on the problems identified in the background section regarding the detection of tuberculosis using existing technologies, the present invention aims to provide a gene encoding an antigen fusion protein of Mycobacterium tuberculosis and its application. The prepared fusion antigen protein has high yield, low cost, simple operation, and good immunogenicity, and can be used for the subsequent development of trivalent subunit vaccines and diagnostic kits. Using this fusion antigen protein, a novel diagnostic reagent for tuberculosis with great application potential can be developed, which can effectively differentiate and diagnose different types of tuberculosis patients.

[0008] This invention is achieved through the following technical solution:

[0009] In a first aspect, this application provides an antigen fusion protein of Mycobacterium tuberculosis, the antigen fusion protein comprising Mycobacterium tuberculosis CFP-10 protein, Rv3369 protein and ESAT-6 protein linked by linker peptides, the amino acid sequence of which is shown in SEQ ID NO: 1.

[0010] Given that Culture Filtrate Protein 10 (CFP10) and Early Secretory Antigenic Target-6 (ESAT6) are unique to Mycobacterium tuberculosis and Mycobacterium bovis, and are lacking in BCG and non-pathogenic mycobacteria, while Rv3369 protein can induce a strong immune response and is an important early secretory antigen produced by Mycobacterium tuberculosis, the fusion antigen protein prepared by this invention has high yield, low cost, simple operation, and good immunogenicity. It can serve as a protein candidate for the development of trivalent subunit vaccines, lay the foundation for the subsequent development of a novel diagnostic reagent for tuberculosis with great application potential, and can also effectively differentiate and diagnose different types of tuberculosis patients.

[0011] Furthermore, the Mycobacterium tuberculosis CFP-10 protein, Rv3369 protein, and ESAT-6 protein are linked by a peptide, wherein the amino acid sequence of the linking peptide is GGGS.

[0012] Secondly, this application provides a gene for an antigen fusion protein, wherein the gene is a gene optimized with E. coli codons, and its nucleotide sequence is shown in SEQ ID NO: 2.

[0013] Furthermore, the gene has a BamHI restriction site at its 5' end, with the nucleotide sequence of BamHI being GGATCC, and an EcoRI restriction site at its 3' end, with the nucleotide sequence of EcoRI being GAATTC.

[0014] Thirdly, this application provides a method for preparing an antigen fusion protein, comprising the following steps:

[0015] 1) Log in to Mycobrowser (https: / / mycobrowser.epfl.ch / ), a professional website for Mycobacterium tuberculosis genome information, and search for and download the gene sequences corresponding to the CFP-10, Rv3369 and ESAT-6 proteins of Mycobacterium tuberculosis.

[0016] 2) Add two linker segments to cfp-10, rv3369 and esat-6 to form a tandem gene cfp-10-linker-rv3369-linker-esat-6;

[0017] 3) Based on the fusion gene sequence, the base sequence of cfp-10-linker 1-rv3369-linker2-esat-6 was optimized using the latest codon optimization software Codonoptimization Tool (https: / / www.vectorbuilder.cn / tool / codon-optimization.html) developed by Yunzhou Biotechnology;

[0018] 4) Add a designed restriction enzyme site BamHI (GGATCC) to the 5' end and a designed restriction enzyme site EcoRI (GAATTC) to the 3' end of the optimized fusion base sequence.

[0019] 5) The BamH I-cfp-10-linker 1-rv3369-linker 2-esat-6-EcoR I DNA fragment was artificially synthesized and ligated into the pET-28a(+) expression vector to construct the pET-28a(+)-cfp-10-linker 1-rv3369-linker 2-esat-6 recombinant expression plasmid;

[0020] 6) The recombinant plasmid pET-28a(+)-cfp-10-linker 1-rv3369-linker 2-esat-6 was transformed into BL21(DE3) competent cells to obtain the expression strain: BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6;

[0021] 7) IPTG was used to induce expression in strain BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6, and SDS-PAGE was used to detect whether the CFP10-Rv3369-ESAT6 fusion protein was successfully expressed, and whether it was expressed as a soluble protein or an inclusion body protein.

[0022] 8) Expand the culture of BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6, collect the bacterial cells, sonicate them, and centrifuge to separate the supernatant and inclusion body precipitate.

[0023] 9) The supernatant from the sonication of the recombinant bacteria was purified using a Ni column and the imidazole elution concentration was optimized;

[0024] 10) Quality control and purification of protein CFP10-Rv3369-ESAT6.

[0025] Furthermore, the recombinant plasmid pET-28a(+)-cfp-10-linker 1-rv3369-linker2-esat-6 was transformed into BL21(DE3) competent cells using the calcium chloride chemical transformation method.

[0026] Fourthly, this application provides a plasmid comprising the aforementioned antigen fusion protein gene.

[0027] Fifthly, this application provides a strain comprising the aforementioned antigen protein gene or a plasmid containing the aforementioned antigen protein gene.

[0028] Sixthly, this application provides a trivalent vaccine, comprising the above-described antigen fusion protein or an antigen fusion protein prepared using the above-described preparation method.

[0029] Seventhly, this application provides a diagnostic kit comprising a specific antibody induced by the antigen fusion protein described above or prepared by the antigen fusion protein prepared by the above method.

[0030] Compared with the prior art, the present invention has the following advantages and beneficial effects:

[0031] This invention prepared a BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 expression strain. By culturing this recombinant strain in LB medium, an antigen fusion protein possessing the characteristics of three Mycobacterium tuberculosis proteins can be obtained. Experiments have shown that the obtained fusion protein is easy to purify, has high yield and good stability, and can be used for the subsequent development of trivalent subunit vaccines and diagnostic kits. Attached Figure Description

[0032] To more clearly illustrate the technical solutions of the exemplary embodiments of the present invention, the accompanying drawings used in the embodiments will be briefly described below. It should be understood that the following drawings only show some embodiments of the present invention and should not be considered as a limitation of the scope. For those skilled in the art, other related drawings can be obtained based on these drawings without creative effort. In the drawings:

[0033] Figure 1 A schematic diagram of the construction of the recombinant plasmid for the pET-28a(+)-cfp-10-rv3369-esat-6 expression vector;

[0034] Figure 2 The image shows the identification results of the pET-28a(+)-cfp-10-rv3369-esat-6 recombinant expression plasmid before and after double digestion with BamHI and EcoRI.

[0035] Figure 3 SDS-PAGE image of the fusion protein;

[0036] 1: Protein Marker;

[0037] 2: BL21(DE3)-pET-28a(+) was induced to express at 37℃ for 4 h;

[0038] 3: Uninduced BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6;

[0039] 4: BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 was induced to express at 37℃ for 4 h;

[0040] Figure 4 SDS-PAGE images for identifying soluble expression of fusion proteins;

[0041] Among them, 1: BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 whole bacterial protein;

[0042] 2: BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 inclusion body protein;

[0043] 3: BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 supernatant;

[0044] 4: Protein Marker;

[0045] Figure 5 SDS-PAGE image of the purification results of the fusion protein in the supernatant of BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6;

[0046] Among them, 1: BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 whole bacterial protein;

[0047] 2: Supernatant protein;

[0048] 3: The effluent from the supernatant protein after passing through a Ni column;

[0049] 4-8: Elution fraction of 50mM imidazole;

[0050] 9-14: Elution fraction of 100mM imidazole;

[0051] 15: Protein Marker.

[0052] Figure 6 SDS-PAGE image for purity and concentration determination of CFP-10-Rv3369-ESAT-6 fusion protein;

[0053] 1-7: BSA protein concentrations of 10, 5, 2.5, 1.25, 0.625, 0.31, and 0.16 mg / mL, respectively;

[0054] 8: Protein Marker;

[0055] 9: Purified CFP-10-Rv3369-ESAT-6 fusion protein.

[0056] Figure 7 SDS-PAGE image of protein stability assay;

[0057] 1-3: CFP-10-Rv3369-ESAT-6 protein stored at 4℃ for 0h in volumes of 2μL, 1μL, and 0.5μL, respectively;

[0058] 4-6: CFP-10-Rv3369-ESAT-6 protein stored at 4℃ for 24h in volumes of 2μL, 1μL, and 0.5μL respectively;

[0059] 7: Protein Marker.

[0060] Figure 8 Western blot analysis of the CFP-10-Rv3369-ESAT-6 fusion protein;

[0061] 1: CFP-10-Rv3369-ESAT-6 purified protein;

[0062] 2: BSA protein;

[0063] 3: Protein Marker. Detailed Implementation

[0064] To make the objectives, technical solutions, and advantages of the present invention clearer, the present invention will be further described in detail below with reference to the embodiments and accompanying drawings. The illustrative embodiments and descriptions of the present invention are only used to explain the present invention and are not intended to limit the present invention.

[0065] In the following description, numerous specific details are set forth in order to provide a thorough understanding of the invention. However, it will be apparent to those skilled in the art that these specific details are not necessary to practice the invention. In other embodiments, well-known materials or methods have not been specifically described in order to avoid obscuring the invention.

[0066] Throughout this specification, references to "an embodiment," "an example," or "an example" mean that a particular feature, structure, or characteristic described in connection with that embodiment or example is included in at least one embodiment of the invention. Therefore, the phrases "an embodiment," "an example," "an example," or "an example" appearing in various places throughout the specification do not necessarily refer to the same embodiment or example. Furthermore, specific features, structures, or characteristics can be combined in one or more embodiments or examples in any suitable combination and / or sub-combination. Moreover, those skilled in the art will understand that the illustrations provided herein are for illustrative purposes and are not necessarily drawn to scale. The term "and / or" as used herein includes any and all combinations of one or more of the associated listed items.

[0067] Example 1

[0068] Construction of the BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 expression strain.

[0069] Log in to Mycobrowser (https: / / mycobrowser.epfl.ch / ), a professional website for Mycobacterium tuberculosis genome information, and search for and download the gene sequences corresponding to the CFP-10, Rv3369, and ESAT-6 proteins of Mycobacterium tuberculosis. For example... Figure 1 As shown, the three gene sequences cfp-10, rv3369, and esat-6 are tandemly linked, with a linker sequence (amino acid sequence GGGGS, nucleotide sequence GGCGGCGGCGGTTCT) added to the middle of each gene. To facilitate the ligation of the fusion gene to the expression vector, a restriction enzyme site BamHI (nucleotide sequence GGATCC) is added to the 5' end of the fusion gene, and a restriction enzyme site EcoRI (nucleotide sequence GAATTC) is added to the 3' end.

[0070] The protein sequence of CFP-10 is as follows:

[0071] MAEMKTDAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQAAVV RFQEAANKQKQELDEISTNIRQAGVQYSRADEEQQQALSSQMGF.

[0072] The protein sequence of Rv3369 is as follows:

[0073] MWAGYRWAMSVELTQEVSARLTSDLYGWLTTVARSGQPVPRLVWFYFDGTDLTVYS MPQAAKVAHITAHPQVSLNLDSDGNGAGIIVVGGTAAVVATDVDCRDDAPYWAKYREDAAKFGLTEAIAAYSTRLKITPTRVWTTPTG.

[0074] The protein sequence of ESAT-6 is as follows:

[0075] MTEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQGVQQK WDATATELNNALQNLARTISEAGQAMASTEGNVTGMFA.

[0076] The amino acid sequence of the antigen fusion protein is as follows:

[0077] MAEMKTDAATLAQEAGNFERISGDLKTQIDQVESTAGSLQGQWRGAAGTAAQAAVVRFQEAANKQKQELDEISTNIRQAGVQYSRADEEQQQALSSQMGFGGGGSMWAGYRWAMSVELTQEVSARLTSDLYGWLTTVARSGQPVPRLVWFYFDGTDLTVYSMPQAAKVAHITAHP QVSLNLDSDGNGAGIIVVGGTAAVVATDVDCRDDAPYWAKYREDAAKFGLTEAIAAYSTRLKITPTRVWTTPTGGGGGSMTEQQWNFAGIEAAASAIQGNVTSIHSLLDEGKQSLTKLAAAWGGSGSEAYQGVQQKWDATATELNNALQNLARTISEAGQAMASTEGNVTGMFA.

[0078] Considering that the expression efficiency of genes in Mycobacterium tuberculosis in Escherichia coli may be affected by codon bias, this invention uses Yunzhou's online codon optimization software, Codon Optimization Tool, to optimize the base sequence of the fusion gene, using the optimized sequence cfp-10-rv3369-esat-6 obtained through whole-gene synthesis.

[0079] The gene sequence of cfp-10 is as follows:

[0080] ATGGCCGAAATGAAAACTGATGCCGCGACTTTAGCGCAGGAAGCGGGCAACTTTGAACGCATTTCTGGTGATCTGAAAACCCAGATTGATCAGGTGGAAAGTACCGCCGGCAGCCTGCAGGGCCAGTGGCGCGGCGCCGCGGGCACCGCG GCGCAGGCGGCGGTAGTGCGTTTCCAGGAAGCGGCGAACAAACAGAAACAGGAACTGGATGAAATTAGCACCAACATTCGCCAGGCGGGTGTACAGTACAGCCGTGCGGATGAAGAACAGCAGCAGGCCCTGAGCAGCCAGATGGGCTTT.

[0081] The gene sequence of rv3369 is as follows:

[0082] ATGTGGGCGGGCTACCGTTGGGCTATGAGCGTGGAACTGACCCAGGAAGTTAGCGCGCGTCTGACCAGCGATCTGTATGGCTGGCTGACCACGGTAGCGCGTAGCGGCCAGCCGGTCCCGCGCCTGGTATGGTTTTATTTTGATGGCACCGATCTGACCGTGTATTCTATGCCGCAGGCGGCGAAAGTGGCCCATATTACCGCACACCCGCAGGTA AGCCTGAATCTGGATAGCGATGGTAATGGCGCGGGCATTATTGTGGTGGGCGGTACCGCAGCCGTGGTGGCAACCGATGTCGACTGTCGTGATGACGCGCCGTATTGGGCCAAATACCGCGAAGATGCCGCCAAATTTGGCCTGACCGAAGCAATTGCGGCGTATAGCACCCGTCTGAAAATTACCCCGACCCGTGTGTGGACCACCCCGACCGGC.

[0083] The gene sequence of esat-6 is as follows:

[0084] ATGACCGAACAGCAGTGGAACTTTGCGGGCATTGAAGCGGCGGCGTCAGCCATTCAGGGCAACGTCACCAGCATTCATAGCCTGCTGGATGAAGGCAAACAGAGTCTGACGAAACTGGCGGCCGCGTGGGGTGGTAGCGGCAGC GAAGCCTATCAGGGAGTGCAACAGAAATGGGATGCCACCGCAACGGAACTGAATAACGCGCTGCAGAATCTGGCCCGCACCATTAGCGAAGCGGGCCAGGCGATGGCCAGCACGGAAGGCAACGTGACCGGCATGTTCGCGTAA.

[0085] The optimized gene sequence of cfp-10-rv3369-esat-6 is as follows:

[0086]

[0087] The synthesized cfp-10-rv3369-esat-6 fusion gene and expression vector pET-28a(+) were digested using restriction endonucleases BamHI and EcoRI, respectively. The two fragments were then assembled into a recombinant plasmid using T4 ligase. The ligation system is shown in Table 1.

[0088] Table 1. T4 ligase ligation reaction system

[0089]

[0090] The ligation product was transformed into DH5α competent cells, and the specific steps are as follows:

[0091] (1) Add 10 μL of ligation product to 100 μL of DH5α competent cells (Note: add below the liquid surface and gently pipette), then quickly and gently rotate the EP tube twice and immediately place it on ice for 30 min.

[0092] (2) After the ice bath is completed, transfer to a 42℃ water bath for 75 seconds (Note: not more than 90 seconds), and then place on ice for 3-5 minutes to cool.

[0093] (3) After the transformation is completed, add 900 μL of LB broth to the reaction tube in a clean bench, and incubate at 37°C and 180 rpm for 60 min with shaking; centrifuge at 5000 rpm for 5 min at room temperature; discard the 900 μL supernatant, aspirate and mix the remaining 100 μL of bacterial culture, spread it on LB-Kan (containing 50 μg / mL kanamycin sulfate) agar plates, and incubate at 37°C for 12-16 h;

[0094] (4) The next day, single clones were selected and cultured in LB-Kan broth. A portion was used for seed preservation; the remainder was used for plasmid extraction. The correct strain was identified by enzyme digestion and sequencing, and named DH5α-pET-28a(+)-cfp-10-rv3369-esat-6. It was then stored in 10% glycerol at -80°C. (Enzyme digestion identification system components are shown in Table 2; enzyme digestion identification is as follows...) Figure 2 (As shown).

[0095] Table 2 Enzyme digestion reaction system and reaction procedure

[0096]

[0097]

[0098] The correctly sequenced DH5α-pET-28a(+)-cfp-10-rv3369-esat-6 was seeded into 10 mL of LB broth. After overnight culture, the plasmid pET-28a(+)-cfp-10-rv3369-esat-6 was extracted and transformed into BL21(DE3) competent cells along with the empty vector pET-28a(+). Single clones of BL21(DE3)pET-28a(+) and BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 were selected from the transformed plates and seeded into 8 mL of LB medium (containing 50 μg / mL kanamycin sulfate) and cultured until OD500. 600 The value was 0.5-0.8. BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 was divided into two parts. One part of the test tube culture medium was added with a final concentration of 0.2mM IPTG, and the other part was not added with an inducer (as a control). Expression was induced at 37℃ for 4h.

[0099] Centrifuge the induced culture medium at 12000 rpm for 5 min, remove the supernatant, resuspend the precipitate in PBS, and finally add SDS-PAGE loading buffer. Heat the sample at 100℃ for 10 min, then centrifuge and collect the supernatant for electrophoresis. Electrophore at 120V until the bromophenol blue band migrates to 1 cm from the bottom of the gel. Remove the gel and destain it using a protein gel electrophoresis system (the expression effect of the fusion protein is as follows). Figure 3 (As shown).

[0100] Centrifuge the induced culture medium at 12000 rpm for 5 min, remove the supernatant, and resuspend the precipitate in PBS solution containing the protease inhibitor PMSF. Disrupt the bacterial cells using an ultrasonic homogenizer, centrifuge at 12000 rpm at 4℃, and collect the supernatant (soluble expressed protein) and the precipitate (inclusion body expressed protein). Add SDS-PAGE loading buffer to each sample and heat at 100℃ for 10 min, then centrifuge and collect the supernatant for electrophoresis. Electrophoresis is performed at 120V until the bromophenol blue band migrates to 1 cm from the bottom of the gel. Remove the gel and destain using a protein gel electrophoresis system (the effect of distinguishing between soluble and inclusion body expression is shown in the image). Figure 4 (As shown).

[0101] Example 2

[0102] Large-scale expression and purification of the CFP-10-Rv3369-ESAT-6 fusion protein.

[0103] At an inoculation rate of 1%, the primary inoculum was inoculated into 10 L of LB liquid medium containing Kan (secondary inoculum). BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 was cultured at 37°C with shaking at 220 rpm for approximately 3-5 hours until the bacterial OD of the culture reached its maximum. 600 The value reached approximately 0.8. IPTG was added to a final concentration of 0.2 mM, and the cells were collected by centrifugation after induction at 37°C for 9 hours.

[0104] Whole bacteria were resuspended in lysis buffer (20 mM Tris, 300 mM NaCl, 10 mM Imidazole, 1% Triton X-100, 1 mM DTT, 1 mM PMSF, pH 7.2). The proteins were lysed by sonication, centrifuged at 12,000 rpm for 20 min at 4 °C, and the soluble fraction of the expressed protein was purified by nickel ion affinity chromatography.

[0105] The Ni-IDA affinity chromatography column was equilibrated with lysis buffer. After sample loading and supernatant, the target protein was eluted with equilibration buffers containing different concentrations of imidazole. Each eluted fraction was collected for SDS-PAGE analysis. The results showed that the protein eluted with 50 mM imidazole had higher purity. The analytical results are as follows: Figure 5 As shown.

[0106] Samples from Lanes 5-8 were collected and added to processed dialysis bags. Imidazole was removed at 4°C by dialysis in dialysis buffer [1×PBS (pH 7.4), 4 mM GSH, 0.4 mM GSSG, 0.4 M L-Arginine]. The CFP-10-Rv3369-ESAT-6 protein was finally dialyzed in a storage solution of 1×PBS (pH 7.4) for approximately 6-8 hours. After dialysis, the supernatant was filtered through a 0.22 μm filter, aliquoted, and stored at -80°C.

[0107] Example 3

[0108] Quality control of the CFP-10-Rv3369-ESAT-6 fusion protein.

[0109] 1. Determination of CFP-10-Rv3369-ESAT-6 protein concentration and purity

[0110] Protein concentration was determined using the Bradford Protein Assay Kit with BSA as the standard. The results showed a protein concentration of 0.876 mg / mL. SDS-PAGE gel staining with R250 indicated a protein purity >95% (e.g., ...). Figure 6 (As shown).

[0111] 2. Protein stability test (freeze-thaw experiment)

[0112] Take one vial of CFP-10-Rv3369-ESAT-6 protein frozen at -80℃ and place it in an ice-water bath for 5-10 minutes to allow it to thaw slowly. Divide the thawed protein sample in two. Immediately add protein loading buffer to one portion and boil in a water bath for 5 minutes, then store at -20℃ for later use. Place the other portion in a refrigerator at 4℃ for 24 hours, then add protein loading buffer and boil in a water bath for 5 minutes. Perform SDS-PAGE analysis on 2 μL, 1 μL, and 0.5 μL of the sample, respectively. Figure 7 As shown, the protein undergoes slight degradation, but it still retains most of its original properties, indicating that the fusion protein is relatively stable.

[0113] 3. Reactivity analysis of CFP-10-Rv3369-ESAT-6 protein

[0114] The Western blot (WB) experiment was performed according to the guidelines in "Experimental Techniques of Protein Electrophoresis" (by Guo Yaojun), using anti-His antibody. Results showed that CFP-10-Rv3369-ESAT-6 fused with His and could be recognized by the anti-His antibody (e.g., ...). Figure 8 (As shown).

[0115] 4. Immunogenicity analysis of CFP-10-Rv3369-ESAT-6 protein

[0116] Five 6-8 week old female BALB / c mice were selected and immunized with a mixture of CFP-10-Rv3369-ESAT-6 protein and Freund's adjuvant, administered via intraperitoneal injection at a dose of 50 μg per mouse, with a booster immunization every 2-3 weeks. Blood samples were collected, and the titer of antiserum against CFP-10-Rv3369-ESAT-6 protein was determined by indirect ELISA. The results showed that the serum titer of anti-CFP-10-Rv3369-ESAT-6 protein was approximately 81K after three immunizations (Table 3), indicating that CFP-10-Rv3369-ESAT-6 has good immunogenicity and can be used as a candidate protein for vaccines.

[0117] Table 3. Indirect ELISA results of mouse serum anti-CFP-10-Rv3369-ESAT-6 after triple immunization.

[0118]

[0119]

[0120] The specific embodiments described above further illustrate the purpose, technical solution, and beneficial effects of the present invention. It should be understood that the above description is only a specific embodiment of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principles of the present invention should be included within the scope of protection of the present invention.

Claims

1. An antigen fusion protein of Mycobacterium tuberculosis, characterized in that, The antigen fusion protein comprises Mycobacterium tuberculosis CFP-10 protein, Rv3369 protein, and ESAT-6 protein linked by a linker peptide, and its amino acid sequence is shown in SEQ ID NO:

1.

2. The Mycobacterium tuberculosis antigen fusion protein according to claim 1, characterized in that, The Mycobacterium tuberculosis CFP-10 protein, Rv3369 protein, and ESAT-6 protein are linked by peptides.

3. A gene encoding the antigen fusion protein of claim 1 or claim 2, characterized in that, The gene is a gene optimized with E. coli codons, and its nucleotide sequence is shown in SEQ ID NO:

2.

4. A method for preparing the antigen fusion protein according to claim 1 or claim 2, characterized in that, Includes the following steps: Download the gene sequences corresponding to the CFP-10, Rv3369, and ESAT-6 proteins of Mycobacterium tuberculosis. Two linker segments were added to cfp-10, rv3369 and esat-6 to form a tandem gene cfp-10-linker 1-rv3369-linker 2-esat-6; The base sequence of cfp-10-linker 1-rv3369-linker 2-esat-6 was optimized; A designed restriction enzyme site, BamHI, was added to the 5' end of the optimized fusion sequence, and a designed restriction enzyme site, EcoRI, was added to the 3' end. A BamHI-cfp-10-linker 1-rv3369-linker 2-esat-6-EcoRI DNA fragment was artificially synthesized and ligated into the pET-28a(+) expression vector to construct the pET-28a(+)-cfp-10-linker 1-rv3369-linker2-esat-6 recombinant expression plasmid. The recombinant plasmid pET-28a(+)-cfp-10-linker 1-rv3369-linker 2-esat-6 was transformed into BL21(DE3) competent cells to obtain the expression strain: BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6; The expression of the CFP10-Rv3369-ESAT6 fusion protein was induced by IPTG in strain BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6. SDS-PAGE was used to detect whether the CFP10-Rv3369-ESAT6 fusion protein was successfully expressed, and whether it was expressed as a soluble protein or an inclusion body. BL21(DE3)-pET-28a(+)-cfp-10-rv3369-esat-6 was cultured on a large scale, and the bacterial cells were collected and ultrasonically disrupted. The supernatant and inclusion body precipitate were then separated by centrifugation. The supernatant fraction of the recombinant bacteria was purified using a Ni column and the imidazole elution concentration was optimized. Quality control and purification of protein CFP10-Rv3369-ESAT6.

5. The method for preparing an antigen fusion protein according to claim 4, characterized in that, The recombinant plasmid pET-28a(+)-cfp-10-linker 1-rv3369-linker 2-esat-6 was transformed into BL21(DE3) competent cells using the calcium chloride chemical transformation method.

6. A plasmid, characterized in that, Includes the gene described in claim 3.

7. A strain, characterized in that, Includes the gene as described in claim 3 or the plasmid as described in claim 6.

8. A trivalent vaccine, characterized in that, This includes the antigen fusion protein as described in claim 1 or claim 2, or the antigen fusion protein prepared using the preparation method described in claim 4 or claim 5.

Citation Information

Patent Citations

  • Recombinant bovine tuberculosis specific antigen protein with three fused genes and preparation method thereof

    CN101538578A

  • Antigen fusion protein, coding gene and application thereof

    CN113683707A